Shin Nippon Biomedical Laboratories, Ltd. (OTCMKTS: SBLOF) is a Japan‐based contract research organization specializing in nonclinical safety assessment for the pharmaceutical, biotechnology and agrochemical industries. Established in 1978 and headquartered in Kagoshima, the company provides a range of preclinical testing services designed to support drug development from early discovery through regulatory submission. SBLOF is known for its adherence to Good Laboratory Practice (GLP) standards and its focus on high‐quality data generation and compliance.
The company’s core services include toxicology studies, pharmacokinetics and bioanalysis, safety pharmacology, pathology and genetic toxicology. Using both rodent and non‐rodent models, SBLOF conducts acute, subchronic and chronic toxicity evaluations, as well as specialized studies such as reproductive and developmental toxicity. In addition to in vivo testing, the firm offers in vitro assays, biomarker analysis and method development to support both small‐molecule and biologic drug candidates.
SBLOF operates multiple GLP-compliant laboratories in Japan, including sites in Kagoshima and Tsukuba, and maintains collaboration agreements with facilities in Asia and North America to serve a global client base. The company’s geographic footprint enables it to accommodate diverse client requirements, from local biotech firms seeking regional expertise to multinational corporations conducting cross‐border programs.
Over its four decades of operation, Shin Nippon Biomedical Laboratories has maintained a focus on regulatory alignment and scientific rigor, guided by an experienced executive team based in Japan. The company continues to invest in facility upgrades, staff training and method validation to meet evolving industry standards and support the advancement of novel therapeutics.
AI Generated. May Contain Errors.
Free SBLOF Stock Alerts